Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
AssigneeTemple University of the Commonwealth System of Higher Education
InventorsE. Premkumar Reddy, M.V. Ramana Reddy, James F. Holland, Lewis R. Silverman, Svetlana Zinzar
Life of this patent
Estimating the term…
Abstract
Methods and compositions are provided for treating myelodysplastic syndrome and acute myeloid leukemia, wherein the composition comprises at least one compound according to Formula I: wherein R1 is selected from the group consisting of —NH2, —NH—CH2—CO2H, —NH—CH(CH3)—CO2H, and —NH—C(CH3)2—CO2H, or a pharmaceutically acceptable salt of such a compound; and a DNA methyltransferase inhibitor, or a pharmaceutically acceptable salt thereof.
Claims33
A composition comprising at least one compound according to Formula I:
- wherein R1 is selected from the group consisting of —NH2, —NH—CH2—CO2H, —NH—CH(CH3)—CO2H, and —NH—C(CH3)2—CO2H, or a pharmaceutically acceptable salt of such a compound, and at least one DNA methyltransferase inhibitor, or a pharmaceutically acceptable salt thereof.
A method of treating an individual for myelodysplastic syndrome or acute myeloid leukemia, comprising administering to the individual in need of such treatment, an effective amount of at least one compound according to Formula I:
- wherein R1 is selected from the group consisting of —NH2, —NH—CH2—CO2H, —NH—CH(CH3)—CO2H, and —NH—C(CH3)2—CO2H, or a pharmaceutically acceptable salt of such a compound, and at least one DNA methyltransferase inhibitor, or a pharmaceutically acceptable salt thereof.
A kit comprising, in a first compartment, a compound according to Formula I:
- wherein R1 is selected from the group consisting of —NH2, —NH—CH2—CO2H, —NH—CH(CH3)—CO2H, and —NH—C(CH3)2—CO2H, or a pharmaceutically acceptable salt of such a compound, and, in a second compartment, a DNA methyltransferase inhibitor, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.